Half-maximal inhibitory concentration (IC₅₀), half-maximal cytotoxic concentration (CC₅₀), and selectivity index (SI) of CTLL formulation and its ingredients. by Prapaporn Chaniad (9761710)

Half-maximal inhibitory concentration (IC₅₀), half-maximal cytotoxic concentration (CC₅₀), and selectivity index (SI) of PSCD formulation and its ingredients. by Prapaporn Chaniad (9761710)

Identification of metabolites with cell type-specific-dynamics reveals the amino acid class as highly conserved in hiPSC and hNSC and that most of the cell type-specific amino acid... by João Vasconcelos e Sá (8721594)

Definitions of the features selected [50]. by Yu Zhang (12946)

Discovery of a Colon-Targeted Azo Prodrug of Tofacitinib through the Establishment of Colon-Specific Delivery Systems Constructed by 5‑ASA–PABA–MAC and 5‑ASA–PABA–Diamine for the T... by Jiaxing Zhao (3965057)

“…Specifically, compound <b>20g</b> displayed a 3.67-fold decrease of plasma AUC_{(tofacitinib, 0–∞)} and a 9.61-fold increase of colonic AUC_{(tofacitinib, 0–12h)}, compared with tofacitinib at a molar equivalent oral dose. …”

Viral measurements do not predict off-ART rebound in d4 and d5 ART RMs. by Brandon F. Keele (7450001)

In house finch Harderian glands, we identified ˜90% fewer differentially expressed genes when comparing non-infected controls to MG-infected birds from populations that are more to... by Amberleigh E. Henschen (3257235)

Effects of ethyl acetate extract on the ultrastructure of <i>S</i>. <i>aureus</i> and MRSA as observed by SEM (A, control; B, <i>S</i>. <i>aureus</i>; C, MRSA). by Shivankar Agrawal (11565095)

Subjects:

Effect of Safr and Cands on the levels of complex I (U/mg protein), complex II (U/mg protein), complex IV (U/mg protein), caspase-3 (Casp-3, μg/mg protein), Fas ligand (FasL, μg/mg... by Nagwa Ibrahim Shehata (17319689)

Subjects:

Fig 5 - by Lingru Ruan (18995544)

Fig 5 - by Harshita Sharma (4836180)

The basic characteristics of the included studies. by Junyin Pan (20700411)

Subjects:

Common definitions and criteria for metabolic syndrome. by Junyin Pan (20700411)

Subjects:

Assessment of study bias in the included research. by Junyin Pan (20700411)

Subjects:

Results of the effect of dietary anthocyanins on health outcomes, including effect size and heterogeneity analysis. by Junyin Pan (20700411)

Subjects:

Risk of bias assessment for eligible randomized controlled trials. by Junyin Pan (20700411)

Subjects:

Summary of studies identified in the literature search, including studies excluded from the analysis and reasons for exclusion. by Junyin Pan (20700411)

Subjects:

The flow chart of study selection process. by Junyin Pan (20700411)

Subjects:

Data extracted from included studies for the systematic review and meta-analysis. by Junyin Pan (20700411)

Subjects:

Specifications and outcomes of clinical trial studies included in the meta-analysis. by Junyin Pan (20700411)

Subjects: